273 related articles for article (PubMed ID: 17960455)
1. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
Hung JS; Chang MC; Lee PH; Tien YW
World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
[TBL] [Abstract][Full Text] [Related]
2. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
Strosberg JR; Choi J; Cantor AB; Kvols LK
Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
[TBL] [Abstract][Full Text] [Related]
3. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
[TBL] [Abstract][Full Text] [Related]
4. Management of pancreatic neuroendocrine tumors.
Dickson PV; Behrman SW
Surg Clin North Am; 2013 Jun; 93(3):675-91. PubMed ID: 23632152
[TBL] [Abstract][Full Text] [Related]
5. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
7. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
[TBL] [Abstract][Full Text] [Related]
8. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
[TBL] [Abstract][Full Text] [Related]
9. Surgical management of pancreatic neuroendocrine tumors.
Kimura W; Tezuka K; Hirai I
Surg Today; 2011 Oct; 41(10):1332-43. PubMed ID: 21922354
[TBL] [Abstract][Full Text] [Related]
10. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
11. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
12. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
13. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
14. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer.
House MG; Cameron JL; Lillemoe KD; Schulick RD; Choti MA; Hansel DE; Hruban RH; Maitra A; Yeo CJ
J Gastrointest Surg; 2006 Jan; 10(1):138-45. PubMed ID: 16368504
[TBL] [Abstract][Full Text] [Related]
15. Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases.
Iwasaki M; Tsuchida K; Jinnai H; Komatsubara T; Arisaka T; Tsunemi M; Nakano M; Iijima M; Hiraishi H
Intern Med; 2017; 56(5):517-522. PubMed ID: 28250297
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
[TBL] [Abstract][Full Text] [Related]
17. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
van Vliet EI; van Eijck CH; de Krijger RR; Nieveen van Dijkum EJ; Teunissen JJ; Kam BL; de Herder WW; Feelders RA; Bonsing BA; Brabander T; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2015 Nov; 56(11):1647-53. PubMed ID: 26272813
[TBL] [Abstract][Full Text] [Related]
19. [Two cases of neuroendocrine tumors of the pancreas with multiple liver metastases treated by use of degradable starch microspheres and octreotide].
Goto W; Shimizu S; Kotsuka M; Sakae M; Kanazawa A; Tsukamoto T; Yamashita Y; Nishiguchi Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2139-41. PubMed ID: 25731449
[TBL] [Abstract][Full Text] [Related]
20. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ
Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
